Skip to content

Twist Bioscience

US · TWST #1258 by market cap Listed 2018
103.32 -8.30 -7.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

Recent news

  • Rating change
    Piper Sandler Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115
    \u5e02\u573a\u8d44\u8baf · 2026/8/5
  • Rating change
    Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $212
    \u5e02\u573a\u8d44\u8baf · 2026/10/1
  • Rating change
    TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $190
    \u5e02\u573a\u8d44\u8baf · 2026/10/13
  • Rating change
    Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $215
    \u5e02\u573a\u8d44\u8baf · 2026/10/7
  • Rating change
    William Blair Maintains Twist Bioscience(TWST.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/4
  • Rating change
    Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $110
    \u5e02\u573a\u8d44\u8baf · 2026/7/17
  • Rating change
    TD Cowen Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115
    \u5e02\u573a\u8d44\u8baf · 2026/8/4
  • Rating change
    Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $110
    \u5e02\u573a\u8d44\u8baf · 2026/7/16
  • Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $175
    \u5e02\u573a\u8d44\u8baf · 2026/11/16
  • Rating change
    CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Maintains Target Price $120
    \u5e02\u573a\u8d44\u8baf · 2026/8/4
  • Rating change
    Baird Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $115
    \u5e02\u573a\u8d44\u8baf · 2026/8/4
  • A Quick Look at Today's Ratings for Twist Bioscience(TWST.US), With a Forecast Between $135 to $175
    \u5e02\u573a\u8d44\u8baf · 2026/11/14
  • Rating change
    Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $160
    \u5e02\u573a\u8d44\u8baf · 2026/9/17
  • CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Cuts Target Price to $150
    \u5e02\u573a\u8d44\u8baf · 2026/11/13
  • Rating change
    BWS Financial Initiates Twist Bioscience(TWST.US) With Sell Rating, Announces Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/9/10
  • Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q4 Revenue $126.6M, Vs. FactSet Est of $123.5M
    MT Newswires · 2026/11/12
  • Rating change
    Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $190
    \u5e02\u573a\u8d44\u8baf · 2026/9/29
  • Rating change
    BWS Financial Maintains Twist Bioscience(TWST.US) With Sell Rating, Maintains Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/9/18
  • Rating change
    CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $205
    \u5e02\u573a\u8d44\u8baf · 2026/10/12
  • Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Cuts Target Price to $150
    \u5e02\u573a\u8d44\u8baf · 2026/11/13
  • Rating change
    Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $95
    \u5e02\u573a\u8d44\u8baf · 2026/6/24
  • Rating change
    Evercore Downgrades Twist Bioscience(TWST.US) to Hold Rating, Raises Target Price to $102
    \u5e02\u573a\u8d44\u8baf · 2026/7/6
  • Trade.xyz announces the listing of synthetic DNA company TWST.
    Latest · 2026/10/8
  • Rating change
    Guggenheim Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $107
    \u5e02\u573a\u8d44\u8baf · 2026/6/29
  • Rating change
    CCORF Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $120
    \u5e02\u573a\u8d44\u8baf · 2026/7/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.

Twist Bioscience discussion 0 comments

Add a comment